Hansa Biopharma: Secures growth capital supported by two solid quarters - Redeye

Hansa Biopharma has announced a consecutive quarter with robust sales and the company has secured additional SEK 372m of growth capital on good terms. As a result the company has secure capital to 2026. We increase our base case to SEK 120 (115) with a Bull Case of SEK 220 (215) and Bear Case of SEK 15 (15).

Länk till analysen i sin helhet: https://www.redeye.se/research/995513/hansa-biopharma-secures-growth-capital-supported-by-two-solid-quarters?utm_source=finwire&utm_medium=RSS